Question
VIRAL SHEDDING
Do tixagevimab and cilgavimab, 2 long-acting anti–SARS-CoV-2 monoclonal antibodies given in combination, improve symptoms and viral shedding when administered intramuscularly in the thigh or intravenously in persons with early COVID-19?